BL-7010
/ BioLineRx
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 27, 2025
Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
(PubMed, Nutrients)
- "These include gluten-degrading enzymes (e.g., AN-PEP, Latiglutenase, Zamaglutenase), gluten-sequestering agents (e.g., AGY-010, BL-7010), modulators of intestinal permeability (e.g., Larazotide acetate, IMU-856), immune-modulating agents (e.g., ZED1227, AMG 714, EQ102), and strategies for immune tolerization (e.g., TAK-101, KAN-101, Nexvax2). Continued research is essential to validate efficacy, optimize dosing, and ensure safety in broader patient populations. Here, we provide a comprehensive overview of the therapeutic landscape for CeD, analyze the main strengths and limitations of each treatment and highlight promising directions for future management of CeD, altogether evidencing the urgent need to develop effective alternatives for these patients."
Journal • Review • Allergy • Celiac Disease • Immunology
1 to 1
Of
1
Go to page
1